Intel Stock Tripled in a Year, So Where Will It Be in 5 Years?

Intel Q2 revenue rose 25% YoY to $16.1B, with non-GAAP gross margin up 12ppt to 41.8% and adjusted EPS of $0.42 (vs. a loss of $0.10 a year ago). Management raised 2026 capex to >$20B and guided 2027 spending to be significantly higher, but external foundry revenue remains small ($293M) and profitability hinges on Intel 14A winning outside customers. The August secondary stock sale increased shares by ~242M, lifting the share count to ~5.3B (+21% YoY), which dilutes per-share earnings as analysts look for ~2.0 adjusted EPS next year.

Analysis

The market is likely overpaying for the wrong part of the story. The near-term earnings rebound matters less than the fact that Intel is converting balance-sheet capacity into a long-duration manufacturing option whose economics depend on external demand that is still largely unproven. In other words, the equity is trading like a cyclical recovery plus a call option on foundry credibility, but the dilution means each incremental dollar of profit is spread across a meaningfully larger base, which suppresses per-share compounding even if operating trends improve.

The cleanest winners are not necessarily other chip designers, but the semiconductor ecosystem that gets paid regardless of whether Intel wins customers: ASML, AMAT, and LRCX benefit from a multi-year capex runway, while TSM is the real strategic loser only if Intel actually secures volume and delivers acceptable yields. Until then, Intel is likely subsidizing its own manufacturing learning curve, so the second-order effect is that competitors with proven process leadership keep the better ROIC and pricing power. That makes any valuation rerating at Intel vulnerable to a simple question: does external foundry revenue scale fast enough to offset the capital intensity and dilution?

Catalyst timing is asymmetric. Over the next 1-3 months, the October design-kit release and any customer comments will matter more than quarterly revenue prints; over 6-18 months, the key variable is whether external commitments show up before the capex curve steepens further in 2026-27. Contrarian read: the consensus is treating AI/data-center momentum as evidence that the foundry thesis is already working, but that segment can improve while the foundry still destroys equity value. If the stock slips back below the low-$80s without a named volume customer, the market is probably re-pricing this as a product turnaround, not a foundry re-rating.

Key Decisions for Investors

• Stay neutral on INTC for now; require a named 14A customer with volume commitments before paying for the foundry option. Falsifier for the bear case: external foundry revenue inflecting above roughly $1B/quarter or a binding multi-year take-or-pay deal.
• Pair trade: long ASML or AMAT vs short INTC into the 2026-27 capex cycle. Rationale: tool vendors monetize Intel spending whether or not the foundry becomes profitable. Use a stop if Intel announces a hard deferral of 14A capacity or cuts capex below the $20B level.
• Relative-value short: INTC vs TSM if Intel rallies on headline momentum without customer proof. TSM has already monetized foundry credibility; Intel still has to earn it. Cover if Intel secures a tier-one external customer or if foundry gross loss narrows materially for two consecutive quarters.
• Watch-list, not a trade: FTNT only as a marginal validation point for external design wins. The position size is too small to matter to the equity story unless follow-on customers appear.
• If forced to express the thesis with options, consider a small INTC put spread 3-6 months out only on a rally above prior highs; the risk/reward is better on a failed customer-wins narrative than on chasing upside before proof.